|
|
Blood, 1 March 2008, Vol. 111, No. 5, pp. 2833-2842.
Prepublished online as a Blood First Edition Paper on December 19, 2007; DOI 10.1182/blood-2007-03-077685.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
Claire M. Edwards1,2,
James R. Edwards2,3,
Seint T. Lwin3,
Javier Esparza2,
Babatunde O. Oyajobi2,
Brandon McCluskey2,
Steven Munoz3,
Barry Grubbs2, and
Gregory R. Mundy2,3
1 Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN;
2 Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio; and
3 Vanderbilt Center for Bone Biology, Department of Medicine/Clinical Pharmacology, Vanderbilt University, Nashville, TN
There is increasing evidence to suggest that the Wnt signaling pathway plays a critical role in the pathogenesis of myeloma bone disease. In the present study, we determined whether increasing Wnt signaling within the bone marrow microenvironment in myeloma counteracts development of osteolytic bone disease. C57BL/KaLwRij mice were inoculated intravenously with murine 5TGM1 myeloma cells, resulting in tumor growth in bone and development of myeloma bone disease. Lithium chloride (LiCl) treatment activated Wnt signaling in osteoblasts, inhibited myeloma bone disease, and decreased tumor burden in bone, but increased tumor growth when 5TGM1 cells were inoculated subcutaneously. Abrogation of β-catenin activity and disruption of Wnt signaling in 5TGM1 cells by stable overexpression of a dominant-negative TCF4 prevented the LiCl-induced increase in subcutaneous growth but had no effect on LiCl-induced reduction in tumor burden within bone or on osteolysis in myeloma-bearing mice. Together, these data highlight the importance of the local microenvironment in the effect of Wnt signaling on the development of myeloma bone disease and demonstrate that, despite a direct effect to increase tumor growth at extraosseous sites, increasing Wnt signaling in the bone marrow microenvironment can prevent the development of myeloma bone disease and inhibit myeloma growth within bone in vivo.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y.-W. Qiang, B. Hu, Y. Chen, Y. Zhong, B. Shi, B. Barlogie, and J. D. Shaughnessy Jr
Bortezomib induces osteoblast differentiation via Wnt-independent activation of {beta}-catenin/TCF signaling
Blood,
April 30, 2009;
113(18):
4319 - 4330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ashihara, E. Kawata, Y. Nakagawa, C. Shimazaski, J. Kuroda, K. Taniguchi, H. Uchiyama, R. Tanaka, A. Yokota, M. Takeuchi, et al.
{beta}-Catenin Small Interfering RNA Successfully Suppressed Progression of Multiple Myeloma in a Mouse Model
Clin. Cancer Res.,
April 15, 2009;
15(8):
2731 - 2738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Raab, I. Breitkreutz, G. Tonon, J. Zhang, P. J. Hayden, T. Nguyen, J. H. Fruehauf, B. K. Lin, D. Chauhan, T. Hideshima, et al.
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling
Blood,
February 12, 2009;
113(7):
1513 - 1521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Pinzone, B. M. Hall, N. K. Thudi, M. Vonau, Y.-W. Qiang, T. J. Rosol, and J. D. Shaughnessy Jr
The role of Dickkopf-1 in bone development, homeostasis, and disease
Blood,
January 15, 2009;
113(3):
517 - 525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Edwards
Wnt signaling: bone's defense against myeloma
Blood,
July 15, 2008;
112(2):
216 - 217.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Li, A. Pennisi, and S. Yaccoby
Role of decorin in the antimyeloma effects of osteoblasts
Blood,
July 1, 2008;
112(1):
159 - 168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
